Senores Pharmaceuticals Ltd (SENORES) — FY26 Annual Report | 9 September 2026

9 September 2026 · BSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Senores Pharmaceuticals filed its FY 2025-26 annual report with BSE, highlighting financial growth and strategic acquisitions.

🔄 What Changed

Revenue increased to ₹632.63 crores (from ₹398.25 crores), profit after tax to ₹121.53 crores (from ₹58.34 crores), and total assets to ₹1,603.81 crores (from ₹1,226.86 crores). Net debt rose to ₹281.54 crores (from ₹199.38 crores).

🔮 What's Next

The company plans to scale operations in regulated markets, pursue targeted M&A, and expand its portfolio in critical care injectables and API segments.

💡 Investor Takeaway

Senores is strengthening its position in high-growth regulated markets through strategic acquisitions and operational scaling, supported by robust financial growth and compliance.

Senores Pharmaceuticals reported FY 2025-26 revenue of [amount context mismatch] crores, up from ₹398.25 crores, with profit after tax rising to [amount context mismatch] crores from ₹58.34 crores. Total assets grew to ₹1,603.81 crores, and equity to ₹964.54 crores. The company expanded in the US regulated market (70% of revenue) and acquired stakes in Apnar Pharma and Zoraya Pharmaceuticals. It maintains adequate internal controls, with no material audit qualifications except a resolved cash loss at Apnar Pharma. No defaults, frauds, or regulatory breaches were noted.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SENORES ✨ Ask AI About This

About Senores Pharmaceuticals Ltd (SENORES)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹6,226.21 CrP/E: 47.6ROE: 13.5%ROCE: 15.6%

View full SENORES stock details →

📡 Get AI alerts when SENORES files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SENORES — Free

💡 Ask AI about this filing

"How will Senores manage its rising net debt of ₹281.54 crores?""What is the expected revenue contribution from the US market in FY 2026-27?""When will the Apnar Pharma acquisition be fully integrated into financial results?"

Ask AI Free →

📊 More SENORES filings

🟡 Board Meeting — 25 September 2026Senores Pharmaceuticals held its 9th AGM on September 25, 2026 via video conference, adopting audite...
Announcement — 24 September 2026Senores Pharmaceuticals announced that its trading window will close on October 1, 2026, and remain ...
Announcement — 21 September 2026Senores Pharmaceuticals clarified that recent trading volume changes are normal market fluctuations ...
🔴 Announcement — 11 September 2026Senores Pharmaceuticals announced that its subsidiary Apnar Pharma completed a USFDA inspection at i...
🔴 Annual Report — 3 September 2026Senores Pharmaceuticals Ltd (SENORES) held its 9th AGM on September 25, 2026, approving key governan...

See all SENORES filings →

🔥 Also filed on 9 September 2026

INDUSINDBKIndusInd Bank LtdCorporate Action 543745SVS Ventures LtdAnnual Report FSLFirstsource Solutions LtdCorporate Action 544343CapitalNumbers Infotech LtdCorporate Action LODHALodha Developers LtdCorporate Action HORIZONINDHorizon Industrial Parks LtdAnnual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SENORES files new disclosures

Track SENORES filings, board meetings, and corporate actions. Free email alerts at 5 PM.